Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRDLNASDAQ:ENTXNYSEMKT:IGCNASDAQ:IMUX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDLCardiol Therapeutics$1.10+2.8%$1.04$0.77▼$3.12$90.87M0.98364,275 shs198,500 shsENTXEntera Bio$1.95-0.5%$1.93$1.41▼$2.79$88.63M1.5170,935 shs96,107 shsIGCIGC Pharma$0.34+3.0%$0.30$0.25▼$0.55$25.74M1.5339,420 shs214,616 shsIMUXImmunic$0.92-0.3%$1.04$0.83▼$2.11$87.92M1.73719,429 shs445,534 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDLCardiol Therapeutics+2.80%-0.90%+1.85%-8.33%-49.54%ENTXEntera Bio-0.96%-3.94%-5.80%-7.14%-18.07%IGCIGC Pharma-0.30%+10.89%+14.68%+13.13%+33,599,900.00%IMUXImmunic-0.34%-4.52%-16.58%-27.06%-27.75%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRDLCardiol Therapeutics1.5301 of 5 stars3.73.00.00.00.00.00.6ENTXEntera Bio1.9641 of 5 stars3.53.00.00.02.70.80.0IGCIGC Pharma1.7292 of 5 stars3.50.00.00.02.41.70.0IMUXImmunic2.372 of 5 stars3.63.00.00.02.50.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRDLCardiol Therapeutics 3.40Buy$8.67687.88% UpsideENTXEntera Bio 3.00Buy$10.00412.82% UpsideIGCIGC Pharma 3.00Buy$3.881,053.27% UpsideIMUXImmunic 3.25Buy$13.001,316.74% UpsideCurrent Analyst Ratings BreakdownLatest IGC, CRDL, ENTX, and IMUX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025IMUXImmunicB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $5.005/16/2025IMUXImmunicWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/1/2025IMUXImmunicHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/30/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.004/16/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/16/2025IMUXImmunicB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.004/15/2025IMUXImmunicHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/10/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.004/7/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/1/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.003/25/2025IMUXImmunicWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRDLCardiol TherapeuticsN/AN/AN/AN/A$0.32 per shareN/AENTXEntera Bio$223K397.45N/AN/A$0.36 per share5.42IGCIGC Pharma$1.24M21.66N/AN/A$0.08 per share4.20IMUXImmunicN/AN/AN/AN/A$0.64 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRDLCardiol Therapeutics-$20.84M-$0.34N/AN/AN/AN/A-194.40%-129.07%7/14/2025 (Estimated)ENTXEntera Bio-$8.89M-$0.26N/AN/AN/AN/A-107.24%-92.29%8/8/2025 (Estimated)IGCIGC Pharma-$13M-$0.11N/AN/AN/A-714.16%-122.44%-88.40%N/AIMUXImmunic-$93.61M-$1.23N/AN/AN/AN/A-169.55%-118.96%N/ALatest IGC, CRDL, ENTX, and IMUX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025IMUXImmunic-$0.25-$0.25N/A-$0.25N/AN/A5/9/2025Q1 2025ENTXEntera Bio-$0.07-$0.06+$0.01-$0.06N/A$0.04 million3/31/2025Q4 2024CRDLCardiol Therapeutics-$0.08-$0.07+$0.01-$0.07N/AN/A3/28/2025Q4 2024ENTXEntera Bio-$0.08-$0.06+$0.02-$0.06$0.04 million$0.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRDLCardiol TherapeuticsN/AN/AN/AN/AN/AENTXEntera BioN/AN/AN/AN/AN/AIGCIGC PharmaN/AN/AN/AN/AN/AIMUXImmunicN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRDLCardiol Therapeutics0.012.492.49ENTXEntera BioN/A6.616.61IGCIGC Pharma0.021.150.98IMUXImmunicN/A2.712.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRDLCardiol Therapeutics12.49%ENTXEntera Bio14.11%IGCIGC Pharma3.87%IMUXImmunic51.82%Insider OwnershipCompanyInsider OwnershipCRDLCardiol Therapeutics5.25%ENTXEntera Bio10.90%IGCIGC Pharma31.48%IMUXImmunic3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRDLCardiol Therapeutics2082.61 million78.27 millionNot OptionableENTXEntera Bio2045.45 million31.88 millionOptionableIGCIGC Pharma6179.69 million54.60 millionN/AIMUXImmunic7095.82 million87.38 millionOptionableIGC, CRDL, ENTX, and IMUX HeadlinesRecent News About These CompaniesJanus Henderson Group PLC Cuts Stock Holdings in Immunic, Inc. (NASDAQ:IMUX)May 23 at 3:45 AM | marketbeat.comImmunic, Inc. (NASDAQ:IMUX) Given Consensus Rating of "Buy" by AnalystsMay 22 at 3:47 AM | americanbankingnews.comImmunic, Inc. (NASDAQ:IMUX) Given Average Rating of "Buy" by AnalystsMay 19, 2025 | marketbeat.comWilliam Blair Reaffirms Outperform Rating for Immunic (NASDAQ:IMUX)May 18, 2025 | americanbankingnews.comImmunic (IMUX) Expected to Announce Quarterly Earnings on WednesdayMay 9, 2025 | marketbeat.comWilliam Blair Analysts Boost Earnings Estimates for ImmunicMay 6, 2025 | marketbeat.comLeerink Partnrs Has Bullish Estimate for Immunic Q2 EarningsMay 6, 2025 | marketbeat.comResearch Analysts Issue Forecasts for Immunic Q1 EarningsMay 4, 2025 | marketbeat.comImmunic (NASDAQ:IMUX) Receives "Buy" Rating from HC WainwrightMay 3, 2025 | marketbeat.comImmunic Reports Positive Data From Phase 2 CALLIPER Study Of Vidofludimus CalciumMay 2, 2025 | nasdaq.comD. Boral Capital Reiterates "Buy" Rating for Immunic (NASDAQ:IMUX)May 2, 2025 | marketbeat.comImmunic to Participate in Scientific and Industry Conferences in MayMay 2, 2025 | prnewswire.comImmunic, Inc. (NASDAQ:IMUX) Shares Sold by Adage Capital Partners GP L.L.C.May 2, 2025 | marketbeat.comImmunic Talks Up Disability Gains as Phase II MS Therapy Fails on Primary EndpointMay 1, 2025 | biospace.comMS drug shows promise in progressive cases, despite missed trial goalMay 1, 2025 | thepharmaletter.comImmunic CEO says 'nobody should care at all' about missed primary endpoint in MS studyMay 1, 2025 | fiercebiotech.comImmunic drops after mid-stage trial data for multiple sclerosis drugMay 1, 2025 | msn.comImmunic reports reduced disability worsening in progressive multiple sclerosis trialApril 30, 2025 | proactiveinvestors.comImmunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER TrialApril 30, 2025 | prnewswire.comImmunic: A Strong Buy With Imminent Data Readout That Should Send Shares HigherApril 28, 2025 | seekingalpha.comOne Immunic Insider Raised Their Stake In The Previous YearApril 25, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIGC, CRDL, ENTX, and IMUX Company DescriptionsCardiol Therapeutics NASDAQ:CRDL$1.10 +0.03 (+2.80%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.12 +0.02 (+1.82%) As of 05/23/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.Entera Bio NASDAQ:ENTX$1.93 -0.03 (-1.48%) As of 05/23/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.IGC Pharma NYSEMKT:IGC$0.34 +0.01 (+3.04%) Closing price 05/23/2025 03:58 PM EasternExtended Trading$0.32 -0.01 (-3.87%) As of 05/23/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.Immunic NASDAQ:IMUX$0.92 0.00 (-0.34%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.93 +0.01 (+1.24%) As of 05/23/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
